ISTH marks World Thrombosis Day with urgent global call to action
Thrombosis is the underlying cause of 1 in 4 deaths worldwide each…
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig)…


